{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:16:48Z","timestamp":1790309808606,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Are oocyte maturation rates different among 0.1, 0.2 and 0.4\u00a0mg triptorelin used for triggering final oocyte maturation in patients at high risk for ovarian hyperstimulation syndrome (OHSS) undergoing ICSI?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>A dose of 0.1\u00a0mg triptorelin results in similar oocyte maturation rates compared to higher doses of 0.2 and 0.4\u00a0mg in patients at high risk for OHSS undergoing ICSI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>The GnRH agonist triptorelin is widely used instead of hCG for triggering final oocyte maturation, in order to eliminate the risk of severe OHSS in patients undergoing ovarian stimulation for IVF\/ICSI. However, limited data are currently available regarding its optimal dose use for this purpose in patients at high risk for OHSS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>A retrospective study was performed between November 2015 and July 2017 in 131 infertile patients at high risk for severe OHSS undergoing ovarian stimulation for ICSI. High risk for severe OHSS was defined as the presence of at least 19 follicles \u226511\u00a0mm in diameter on the day of triggering final oocyte maturation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Ovarian stimulation was performed with recombinant FSH and GnRH antagonists. Patients received 0.1 (n\u2009=\u200942), 0.2 (n\u2009=\u200946) or 0.4\u00a0mg (n\u2009=\u200943) triptorelin for triggering final oocyte maturation. Hormonal evaluation of FSH, LH, estradiol (E2) and progesterone (PRG) was carried out on the day of triggering final oocyte maturation, 8 and 36\u00a0hours post triggering and 3, 5, 7, and 10\u00a0days after triptorelin administration. During this period, all patients were assessed for symptoms and signs indicative of severe OHSS development. Primary outcome measure was oocyte maturation rate, defined as the number of metaphase II (MII) oocytes divided by the number of cumulus-oocyte-complexes retrieved per patient. Results are expressed as median (interquartile range).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>No significant differences in patient baseline characteristics were observed among the 0.1\u00a0mg, the 0.2\u00a0mg and the 0.4\u00a0mg groups. Regarding the primary outcome measure, no differences were observed in oocyte maturation rate among the three groups compared [82.6% (17.8%) versus 83.3% (18.8%) versus 85.1% (17.2%), respectively, P\u2009=\u20090.686].<\/jats:p>\n                  <jats:p>In addition, no significant differences were present among the 0.1\u00a0mg, 0.2\u00a0mg and 0.4\u00a0mg groups, regarding the number of mature (MII) oocytes [21 (13) versus 20 (6) versus 20 (11), respectively; P\u2009=\u20090.582], the number of oocytes retrieved [25.5 (13) versus 24.5 (11) versus 23 (12), respectively; P\u2009=\u20090.452], oocyte retrieval rate [81.0% (17.7%) versus 76.5% (23.5%) versus 75.0% (22.5), respectively; P\u2009=\u20090.088], the number of fertilized (two pronuclei) oocytes [12.5 (9) versus 14.5 (7) versus 14.0 (8), respectively; P\u2009=\u20090.985], fertilization rate [71.7% (22%) versus 77.1% (19.1%) versus 76.6% (23.3%), respectively; P\u2009=\u20090.525] and duration of luteal phase [7 (1) versus 8 (2) versus 7 (1) days, respectively; P\u2009=\u20090.632]. Moreover, no significant differences were present among the three triptorelin groups regarding serum levels of LH, FSH, E2 and PRG at any of the time points assessed following triggering of final oocyte maturation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>This is a retrospective study, and although there were no differences in the baseline characteristics of the three groups compared, the presence of bias cannot be excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Based on the results of the current study, it appears that triggering final oocyte maturation with a lower (0.1\u00a0mg) or a higher dose (0.4\u00a0mg) of triptorelin, as compared to the most commonly used dose of 0.2\u00a0mg, does not confer any benefit in terms of oocyte maturation rate in patients at high risk for severe OHSS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>No external funding was obtained for this study. There are no conflicts of interest.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/dez105","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:09:35Z","timestamp":1559300975000},"page":"1770-1777","source":"Crossref","is-referenced-by-count":9,"title":["Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?"],"prefix":"10.1093","volume":"34","author":[{"given":"G T","family":"Lainas","sequence":"first","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"},{"name":"Eugonia Unit of Assisted Reproduction, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T G","family":"Lainas","sequence":"additional","affiliation":[{"name":"Eugonia Unit of Assisted Reproduction, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A","family":"Sfontouris","sequence":"additional","affiliation":[{"name":"Eugonia Unit of Assisted Reproduction, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Chatzimeletiou","sequence":"additional","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Venetis","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health and School of Women's and Children's Health UNSW Medicine, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Bosdou","sequence":"additional","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B C","family":"Tarlatzis","sequence":"additional","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G F","family":"Grimbizis","sequence":"additional","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M","family":"Kolibianakis","sequence":"additional","affiliation":[{"name":"Unit of Human Reproduction, First Department of OB\/Gyn, Medical School, Aristotle University, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"2019091012351233900_ref1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Hum Reprod Update"},{"key":"2019091012351233900_ref2","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.fertnstert.2006.05.049","article-title":"Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates","volume":"86","author":"Acevedo","year":"2006","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/oxfordjournals.humrep.a137276","article-title":"Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups","volume":"6","author":"Asch","year":"1991","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref4","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/humrep\/dei475","article-title":"Serum inhibin a, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial","volume":"21","author":"Babayof","year":"2006","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.fertnstert.2007.11.049","article-title":"Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study","volume":"91","author":"Bodri","year":"2009","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.fertnstert.2013.05.038","article-title":"Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger","volume":"100","author":"Borgbo","year":"2013","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1258\/om.2008.080017","article-title":"The confidential enquiry into maternal and Child health (CEMACH). Saving mothers\u2019 lives: reviewing maternal deaths to make motherhood safer 2003\u20132005. The seventh report of the confidential enquiries into maternal deaths in the UK","volume":"1","author":"Bowyer","year":"2008","journal-title":"Obstet Med"},{"key":"2019091012351233900_ref8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.rbmo.2009.11.018","article-title":"Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support","volume":"20","author":"Castillo","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2019091012351233900_ref9","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-free clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1472-6483(10)62105-0","article-title":"Luteal phase defects following agonist-triggered ovulation: a patient-dependent response","volume":"9","author":"Emperaire","year":"2004","journal-title":"Reprod Biomed Online"},{"key":"2019091012351233900_ref11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.fertnstert.2014.01.019","article-title":"Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and \"freeze-all\" approach in GnRH antagonist protocol","volume":"101","author":"Fatemi","year":"2014","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jcem.87.2.8197","article-title":"Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization","volume":"87","author":"Fauser","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019091012351233900_ref14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-015-0160-4","article-title":"Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis","volume":"8","author":"Fensore","year":"2015","journal-title":"J Ovarian Res"},{"key":"2019091012351233900_ref15","doi-asserted-by":"crossref","first-page":"e0149615","DOI":"10.1371\/journal.pone.0149615","article-title":"Prediction of ovarian Hyperstimulation syndrome in patients treated with Corifollitropin alfa or rFSH in a GnRH antagonist protocol","volume":"11","author":"Griesinger","year":"2016","journal-title":"PloS One"},{"key":"2019091012351233900_ref16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5152\/jtgga.2015.15084","article-title":"Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: case series","volume":"16","author":"Gulekli","year":"2015","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"2019091012351233900_ref17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.14740\/jocmr2500w","article-title":"Is it possible to prevent ovarian Hyperstimulation syndrome by gonadotropin-releasing hormone agonist triggering and modified luteal support in patients with polycystic ovarian morphology?","volume":"8","author":"Gurbuz","year":"2016","journal-title":"Journal of clinical medicine research"},{"key":"2019091012351233900_ref18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.fertnstert.2008.03.077","article-title":"No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles","volume":"91","author":"Hernandez","year":"2009","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1210\/jcem-57-4-792","article-title":"Hormonal dynamics at midcycle: a reevaluation","volume":"57","author":"Hoff","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2019091012351233900_ref20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/humupd\/dmr008","article-title":"GnRH agonist for triggering of final oocyte maturation: time for a change of practice?","volume":"17","author":"Humaidan","year":"2011","journal-title":"Hum Reprod Update"},{"key":"2019091012351233900_ref21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rbmo.2011.11.001","article-title":"The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives","volume":"24","author":"Humaidan","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2019091012351233900_ref22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0015-0282(16)54474-4","article-title":"Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist","volume":"56","author":"Itskovitz","year":"1991","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref23","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/j.fertnstert.2012.07.944","article-title":"Triggering final oocyte maturation with GnRH agonist in patients with polycystic ovaries undergoing IVF","volume":"98","author":"Kolibianakis","year":"2012","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref24","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/humrep\/dei106","article-title":"In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF","volume":"20","author":"Lainas","year":"2005","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/humrep\/dep436","article-title":"Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)","volume":"25","author":"Lainas","year":"2010","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2009.05.092","article-title":"Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome","volume":"94","author":"Luke","year":"2010","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/1471-0528.14241","article-title":"Effect of ethnicity on live birth rates after in vitro fertilisation\/intracytoplasmic sperm injection treatment: analysis of UK national database","volume":"124","author":"Maalouf","year":"2017","journal-title":"BJOG"},{"key":"2019091012351233900_ref28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/oxfordjournals.humrep.a137702","article-title":"In-vitro fertilization and the ovarian hyperstimulation syndrome","volume":"7","author":"MacDougall","year":"1992","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.fertnstert.2012.01.092","article-title":"Is there a place for corifollitropin alfa in IVF\/ICSI cycles? A systematic review and meta-analysis","volume":"97","author":"Mahmoud Youssef","year":"2012","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.rbmo.2009.06.001","article-title":"GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study","volume":"19","author":"Melo","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"2019091012351233900_ref31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/oxfordjournals.humrep.a136044","article-title":"Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome","volume":"10","author":"Morris","year":"1995","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1297-9589(00)00064-3","article-title":"Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin [in French]","volume":"29","author":"Parneix","year":"2001","journal-title":"Gynecol Obstet Fertil"},{"key":"2019091012351233900_ref33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/humrep\/del072","article-title":"GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study","volume":"21","author":"Pirard","year":"2006","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref34","doi-asserted-by":"crossref","first-page":"727569","DOI":"10.1155\/2015\/727569","article-title":"Contribution to more patient-friendly ART treatment: efficacy of continuous low-dose GnRH agonist as the only luteal support-results of a prospective, randomized, comparative study","volume":"2015","author":"Pirard","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2019091012351233900_ref35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/humupd\/3.3.255","article-title":"The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome","volume":"3","author":"Rizk","year":"1997","journal-title":"Hum Reprod Update"},{"key":"2019091012351233900_ref36","first-page":"131","volume-title":"In-Vitro Fertilization and Assisted Reproduction","author":"Rizk","year":"1999"},{"key":"2019091012351233900_ref37","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/humrep\/det124","article-title":"Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG","volume":"28","author":"Seyhan","year":"2013","journal-title":"Hum Reprod"},{"key":"2019091012351233900_ref38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejogrb.2009.11.017","article-title":"IVF outcome in women with PCOS, PCO and normal ovarian morphology","volume":"149","author":"Swanton","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2019091012351233900_ref39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.fertnstert.2015.10.014","article-title":"Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study","volume":"105","author":"Vuong","year":"2016","journal-title":"Fertil Steril"},{"key":"2019091012351233900_ref40","first-page":"Cd008046","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","author":"Youssef","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/dez105\/29101168\/dez105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/34\/9\/1770\/29228828\/dez105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T17:52:18Z","timestamp":1568137938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/34\/9\/1770\/5544005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,8,6]]},"published-print":{"date-parts":[[2019,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dez105","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,8,6]]}}}